Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer

被引：8

作者：

Inomata, Minehiko ^{[1
]}

Shimokawa, Kazuki ^{[3
]}

Tokui, Kotaro ^{[3
]}

Taka, Chihiro ^{[3
]}

Okazawa, Seisuke ^{[3
]}

Kambara, Kenta ^{[3
]}

Yamada, Toru ^{[3
]}

Miwa, Toshiro ^{[3
]}

Hayashi, Ryuji ^{[3
]}

Kashii, Tatsuhiko ^{[2
]}

Matsui, Shoko ^{[4
]}

Tobe, Kazuyuki ^{[3
]}

机构：

[1] Toyama Univ Hosp, Clin Res Ctr, Sugitani 2630, Toyama 9300194, Japan

[2] Toyama Univ Hosp, Dept Med Oncol, Toyama, Japan

[3] Toyama Univ, Dept Internal Med 1, Toyama, Japan

[4] Toyama Univ, Ctr Hlth Care & Human Sci, Toyama, Japan

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 09期

关键词：

Epidermal growth factor receptor; lung cancer; elderly; adverse effects; 1ST-LINE TREATMENT; OPEN-LABEL; JAPANESE PATIENTS; PHASE-II; ERLOTINIB; GEFITINIB; CHEMOTHERAPY; MULTICENTER;

D O I：

10.21873/anticanres.11062

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We conducted a retrospective study to investigate the frequency of appetite loss during treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in elderly patients, aged 75 years or older, with non-small cell lung cancer harboring EGFR gene mutations. Patients and Methods: Data of a total of 64 patients, including 39 relatively young (hereinafter, younger) patients and 25 elderly patients were analyzed. Results: Appetite loss of all grades (p=0.074) and of grade 3 or greater (p=0.030) was more frequently observed in elderly patients. Diarrhea and oral mucositis were also more frequent in elderly patients, although they did not reach statistical significance. No apparent differences were observed in the frequency of aspartate aminotransferase/alanine aminotransferase elevation, skin rash or fatigue between the two patient groups. The median (95% confidence interval) progression-free survival times were 10.8 (6.6-16.4) months and 11.8 (4.4-20.3) months in the younger and elderly patient groups, respectively. Conclusion: Our findings suggest that appetite loss is a major adverse effect in elderly patients with non-small cell lung cancer receiving treatment with EGFR-TKIs.

引用

页码：4951 / 4954

页数：4

共 14 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[3] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC) [J].

Goto, Koichi ;

Nishio, Makoto ;

Yamamoto, Noboru ;

Chikamori, Kenichi ;

Hida, Toyoaki ;

Maemondo, Makoto ;

Katakami, Nobuyuki ;

Kozuki, Toshiyuki ;

Yoshioka, Hiroshige ;

Seto, Takashi ;

Fukuyama, Tamaki ;

Tamura, Tomohide .

LUNG CANCER, 2013, 82 (01) :109-114

[4] Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations [J].

Inoue, Yusuke ;

Inui, Naoki ;

Asada, Kazuhiro ;

Karayama, Masato ;

Matsuda, Hiroyuki ;

Yokomura, Koshi ;

Koshimizu, Naoki ;

Imokawa, Shiro ;

Yamada, Takashi ;

Shirai, Toshihiro ;

Kasamatsu, Norio ;

Suda, Takafumi .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) :155-161

[5] First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study [J].

Maemondo, Makoto ;

Minegishi, Yuji ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Harada, Masao ;

Okinaga, Shoji ;

Morikawa, Naoto ;

Oizumi, Satoshi ;

Tanaka, Tomoaki ;

Isobe, Hiroshi ;

Kudoh, Shoji ;

Hagiwara, Koichi ;

Nukiwa, Toshihiro ;

Gemma, Akihiko .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) :1417-1422

[6] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[7] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[8] PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, Luis G. ;

de Marinis, Filippo ;

Dediu, Mircea ;

Thomas, Michael ;

Pujol, Jean-Louis ;

Bidoli, Paolo ;

Molinier, Olivier ;

Sahoo, Tarini Prasad ;

Laack, Eckart ;

Reck, Martin ;

Corral, Jesus ;

Melemed, Symantha ;

John, William ;

Chouaki, Nadia ;

Zimmermann, Annamaria H. ;

Visseren-Grul, Carla ;

Gridelli, Cesare .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2895-+

[9] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[10] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

← 1 2 →